Send us Feedback

AMAG Pharmaceuticals (AMAG)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
AMAG Pharma (AMAG) Declines After Recalling Batch of Rienso
StreetInsider.com  3 hrs ago  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AMAG+Pharma+%28AMAG%29+Declines+After+Recalling+Batch+of+Rienso/8362197.html for the full story.
Amag pulls anemia drug batch after Swiss patient dies
FiercePharma  5 hrs ago  Comment 
Amag Pharmaceuticals and partner Takeda have run into a snag in Switzerland. Japan-based Takeda is recalling a batch of Amag's anemia drug Feraheme, sold as Rienso in the Swiss market, after several reports of hypersensitivity reactions, one...
AMAG Pharmaceuticals (AMAG) Trading Near $24.43 Support Level
Market Intelligence Center  8 hrs ago  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Tuesday's trading session at $25.08. In the past year, the stock has hit a 52-week low of $12.98 and 52-week high of $25.67. AMAG Pharmaceuticals (AMAG) stock has been showing support around $24.43 and...
AMAG Pharmaceuticals (AMAG) Showing Bullish Technicals But Could Break Through $23.80 Resistance
Market Intelligence Center  May 10  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Thursday's trading session at $23.45. In the past year, the stock has hit a 52-week low of $12.43 and 52-week high of $24.56. AMAG Pharmaceuticals (AMAG) stock has been showing support around $23.18 and...
Potential AMAG Pharmaceuticals (AMAG) Trade Targets 21.53% Return
Market Intelligence Center  May 3  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Thursday's trading session at $22.11. In the past year, the stock has hit a 52-week low of $12.43 and 52-week high of $23.98. AMAG Pharmaceuticals (AMAG) stock has been showing support around $21.55 and...
AMAG Pharmaceuticals (AMAG) Could Fall Through $21.40 Support Level
Market Intelligence Center  Apr 29  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Friday's trading session at $21.89. In the past year, the stock has hit a 52-week low of $12.43 and 52-week high of $23.98. AMAG Pharmaceuticals (AMAG) stock has been showing support around $21.40 and...
Cloud Expo New York: Secret Sauce for a Scalable Enterprise Cloud Model
Cloud Computing  Apr 11  Comment 
AMAG Pharmaceuticals’ five-person IT team should bottle its secret sauce for a scalable enterprise cloud model. The public company eliminated its data center in 2008 and has since encouraged employees to adopt cloud applications as they see fit...
AMAG Pharmaceuticals (AMAG) Showing Bullish Technicals But Could Fall Through $23.00 Support
Market Intelligence Center  Apr 1  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) closed Thursday's trading session at $23.85. In the past year, the stock has hit a 52-week low of $12.43 and 52-week high of $23.98. AMAG Pharmaceuticals (AMAG) stock has been showing support around $23.00 and...
AMAG Announces Positive Preliminary from IDA-303 study
Benzinga  Mar 15  Comment 
AMAG Pharmaceuticals (NASDAQ: AMAG) today announced positive preliminary data from the IDA-303 study. IDA-303 is a single arm, open-label extension study that evaluated the safety and efficacy of repeat dosing with ferumoxytol...




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Grant Zeng
www.zacks.com

Amag Pharmaceuticals Inc., formerly known as Advanced Magnetics Inc., develops and markets superparamagnetic iron oxide nanoparticles used in pharmaceutical products. The company is dedicated to the development and commercialization of its proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company has two approved products, Feridex IV and GastroMARK, which are marketed primarily in the U.S. and Europe. Feridex IV is a liver contrast agent, and GastroMARK is an oral contrast agent used for delineating the bowel in MRI. The company has two primary product candidates, Ferumoxytol and Combidex. Ferumoxytol is in phase III multi-center clinical trials for use as an iron replacement therapeutic in chronic kidney disease patients, whether or not on dialysis. Combidex is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from normal lymph nodes.

Amag Pharmaceuticals was incorporated in Delaware in 1981 and is based in Cambridge, Massachusetts.




References

Retrieved from "http://www.wikinvest.com/stock/AMAG_Pharmaceuticals_(AMAG)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki